Efficacy and toxicity of drugs targeting KRAS < sup > G12C < /sup > mutation in non-small cell lung cancer: a meta-analysis

CONCLUSION: Sotorasib, Adagrasib, and Garsorasib as the drugs of choice for patients with KRASG12C mutation NSCLC, have definite efficacy and acceptable safety, especially for patients with advanced or metastatic disease and within posterior line therapy.PMID:37950424 | DOI:10.1080/14737140.2023.2282606
Source: Expert Review of Anticancer Therapy - Category: Cancer & Oncology Authors: Source Type: research